|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
389,580,000 |
Market
Cap: |
50.01(B) |
Last
Volume: |
1,778,975 |
Avg
Vol: |
1,913,734 |
52
Week Range: |
$75.49 - $140.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 487 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
214,480 |
283,298 |
303,316 |
571,262 |
Total Sell Value |
$28,881,982 |
$37,155,070 |
$39,545,240 |
$69,827,197 |
Total People Sold |
7 |
12 |
14 |
16 |
Total Sell Transactions |
14 |
29 |
47 |
80 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Leach Jacob Steven |
EVP Chief Technology Officer |
|
2023-03-08 |
4 |
A |
$0.00 |
$25 |
D/D |
25,397 |
306,486 |
|
- |
|
Lawver Teri L |
EVP Chief Commercial Officer |
|
2023-03-08 |
4 |
A |
$0.00 |
$45 |
D/D |
45,352 |
45,352 |
|
- |
|
Selvaraj Shelly Ramasamy |
SVP Chief Information Officer |
|
2023-03-08 |
4 |
A |
$0.00 |
$11 |
D/D |
10,885 |
60,984 |
|
- |
|
Pacelli Steven Robert |
EVP Managing Director Dexcom V |
|
2023-03-08 |
4 |
A |
$0.00 |
$19 |
D/D |
18,776 |
155,240 |
|
- |
|
Regan Barry J. |
EVP Operations |
|
2023-03-08 |
4 |
A |
$0.00 |
$19 |
D/D |
18,776 |
78,162 |
|
- |
|
Stern Sadie |
EVP Chief Human Resources Offi |
|
2023-03-08 |
4 |
A |
$0.00 |
$22 |
D/D |
21,769 |
90,153 |
|
- |
|
Dolan Matthew Vincent |
SVP Corporate Strategy-Develop |
|
2023-03-08 |
4 |
A |
$0.00 |
$22 |
D/D |
21,769 |
48,305 |
|
- |
|
Brown Micheal Jon |
EVP Chief Legal Officer |
|
2023-03-08 |
4 |
A |
$0.00 |
$22 |
D/D |
21,769 |
70,294 |
|
- |
|
Leach Jacob Steven |
EVP Chief Technology Officer |
|
2023-03-06 |
4 |
AS |
$114.45 |
$2,081,822 |
D/D |
(18,144) |
281,089 |
|
21% |
|
Dolan Matthew Vincent |
SVP Corporate Strategy-Develop |
|
2023-03-06 |
4 |
AS |
$114.40 |
$25,854 |
D/D |
(226) |
26,536 |
|
21% |
|
Sayer Kevin R |
President CEO and Chairman of |
|
2023-03-01 |
4 |
AS |
$109.83 |
$4,228,611 |
D/D |
(38,464) |
331,337 |
|
18% |
|
Pacelli Steven Robert |
EVP Managing Director Dexcom V |
|
2023-02-23 |
4 |
AS |
$111.64 |
$45,996 |
D/D |
(412) |
136,464 |
|
14% |
|
Sylvain Jereme M |
EVP Chief Financial Officer |
|
2023-02-22 |
4 |
AS |
$114.54 |
$274,896 |
D/D |
(2,400) |
64,837 |
|
14% |
|
Regan Barry J. |
EVP Operations |
|
2023-01-30 |
4 |
AS |
$106.12 |
$234,844 |
D/D |
(2,213) |
59,386 |
|
15% |
|
Sayer Kevin R |
President CEO and Chairman of |
|
2023-01-30 |
4 |
AS |
$106.06 |
$6,034,123 |
D/D |
(56,844) |
369,801 |
|
15% |
|
Pacelli Steven Robert |
EVP Managing Director Dexcom V |
|
2023-01-23 |
4 |
AS |
$107.86 |
$44,438 |
D/D |
(412) |
136,876 |
|
12% |
|
Sayer Kevin R |
President CEO and Chairman of |
|
2023-01-20 |
4 |
S |
$105.75 |
$4,822,872 |
D/D |
(45,607) |
426,645 |
|
-9% |
|
Sayer Kevin R |
President CEO and Chairman of |
|
2023-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
90,720 |
472,252 |
|
- |
|
Pacelli Steven Robert |
EVP Managing Director Dexcom V |
|
2022-12-23 |
4 |
AS |
$112.57 |
$46,379 |
D/D |
(412) |
137,288 |
|
8% |
|
Flynn Paul R |
EVP Global Revenue |
|
2022-12-08 |
4 |
AS |
$123.50 |
$1,110,018 |
D/D |
(8,988) |
55,744 |
|
-0% |
|
Regan Barry J. |
EVP Operations |
|
2022-11-21 |
4 |
D |
$112.62 |
$425,818 |
D/D |
(3,781) |
61,599 |
|
- |
|
Sylvain Jereme M |
EVP Chief Financial Officer |
|
2022-11-21 |
4 |
AS |
$112.62 |
$270,288 |
D/D |
(2,400) |
67,237 |
|
3% |
|
Stern Sadie |
EVP Chief Human Resources Offi |
|
2022-11-21 |
4 |
D |
$112.62 |
$432,911 |
D/D |
(3,844) |
68,384 |
|
- |
|
Naganathan Girish |
EVP Chief Technology Officer |
|
2022-11-08 |
4 |
A |
$0.00 |
$31 |
D/D |
31,449 |
31,449 |
|
- |
|
Sayer Kevin R |
President CEO and Chairman of |
|
2022-11-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
381,532 |
|
- |
|
1713 Records found
|
|
Page 6 of 69 |
|
|